Immune related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1 / PD-L1 therapy

Background: Immune-related adverse events (irAEs) are commonly encountered when using anti-PD-1/PD-L1 therapy and are often managed with corticosteroids. The effect of irAEs, particularly when steroids are required, on patient survival is not well established.Methods: In this retrospective analysis, data for 157 patients with various tumor types treated with anti-PD-1/PD-L1 therapy were obtained. Kaplan Meier and Cox regression analyses were used to assess the effect of irAEs and corticosteroids on progression-free survival (PFS).

Source: Seminars in Oncology - August 6, 2018 Category: Cancer & Oncology Authors: Hammad Shafqat, Theodore Gourdin, Amy Sion Source Type: research